ArticleSignal transduction and targeted therapy2026
Potent anti-tumor activity of CD98hc-targeted antibody-drug conjugates in ovarian cancer.
Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ovarian cancer remains a challenging malignancy with high recurrence rates and limited long-term therapeutic success. Antibody-drug conjugates (ADCs) represent a promising therapeutic class capable of delivering potent cytotoxic agents selectively to tumor cells. In this study, we investigated the potential of CD98hc, a transmembrane glycoprotein involved in amino acid transport and cell signaling, as a novel target for ADCs in ovarian cancer. Western blotting and immunohistochemistry analyses revealed higher CD98hc expression in ovarian tumor tissues compared to normal ovarian tissue. Flow cytometry and immunofluorescence studies confirmed that an antibody against the extracellular domain of CD98hc bound cell surface CD98hc and internalized to lysosomes. Using this antibody, we generated ADCs containing the payloads DM1, MMAF, or DXd. Among these, the anti-CD98hc-MMAF construct showed superior cytotoxicity in ovarian cancer cell lines, with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.